Riskpilot← Back to searchSign inGet full accessEurofins Genomics Denmark A/S
A/SActiveCVR 10048818Smedeskovvej 38Research and experimental development on natural sciences and engineering · NACE 7210Est. 200063 employees
Revenue 2024
DKK 36,8M
+112% vs 2023
EBITDA margin
-0.3%
+99% vs 2023
Equity ratio
-2.4%
Financial strength
Net profit 2024
DKK -12,8M
+38% vs 2023
| Revenue | DKK 36,8M | +112% |
| EBITDA | DKK -96K | +99% |
| Net profit | DKK -12,8M | +38% |
| Total assets | DKK 175,3M | +30% |
| Equity | DKK -4,1M | -123% |
| Employees | 63 | — |
Legal name
Eurofins Genomics Denmark A/S
CVR number
10048818
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. november 2000
Share capital
DKK 550.000
Employees
63 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af bestyrelsesformanden i forening med direktøren eller et bestyrelsesmedlem.
Company purpose
Selskabets formål er kontraktforskning, laboratoriemæssig service og handel med knowhow og laboratorieydelser.
Address
Smedeskovvej 38
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 40.932 | 104.253 | 27.206 | 17.331 | 36.823 |
| Staff expenses | -22.894 | -48.493 | -35.371 | -33.558 | -36.794 |
| EBITDA | 18.038 | 55.761 | -8.165 | -16.227 | -96 |
| Depreciation & amort. | -2.934 | -13.375 | -6.707 | -6.874 | -8.988 |
| EBIT | 15.104 | 42.386 | -14.872 | -23.101 | -9.084 |
| Net financials | -316 | -881 | -1.602 | -3.491 | -5.440 |
| Profit before tax | 14.788 | 41.505 | -16.474 | -26.592 | -14.525 |
| Tax | 3.253 | 9.154 | -3.556 | -5.850 | -1.712 |
| Net profit | 11.534 | 32.351 | -12.918 | -20.742 | -12.812 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 105.845 | 123.921 | 77.042 | 134.500 | 175.330 |
| Equity | 23.003 | 49.855 | 15.936 | 17.796 | -4.144 |
| Long-term debt | 22.798 | 22.527 | 40.599 | 59.256 | 103.355 |
| Short-term debt | 58.846 | 51.539 | 20.507 | 56.874 | 75.419 |
| Total debt | 82.842 | 74.066 | 61.106 | 116.130 | 178.774 |
EBITDA margin
-0.3%
This company
15.8%
Market median
-102% vs market
20202024
Equity ratio
-2.4%
This company
38.2%
Market median
-106% vs market
20202024
Return on equity
-1281229500.0%
This company
18.4%
Market median
-6963203904% vs market
20202024
Net profit margin
-34.8%
This company
8.1%
Market median
-530% vs market
20202024
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20202024
Debt / equity
43.30×
This company
0.62×
Market median
-6884% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
TF Founder | Founder | 2000 |
JS Chief Executive Officer | Chief Executive Officer | 2018 |
TT Founder | Founder | 2000 |
MK Founder | Founder | 2000 |
| Former (3) | ||
BS Chief Executive Officer | Chief Executive Officer | 2009 – 2013 |
MM Chief Executive Officer | Chief Executive Officer | 2013 – 2016 |
DS Chief Executive Officer | Chief Executive Officer | 2017 – 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2013 | |
| Board of Directors | 2024 | |
| Former (14) | ||
| Board of Directors | 2000 – 2004 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2011 – 2013 | |
| Board of Directors | 2009 – 2010 | |
| Board of Directors | 2013 – 2015 | |
| Board of Directors | 2003 – 2013 | |
| Board of Directors | 2020 – 2023 | |
| Board of Directors | 2013 – 2020 | |
| Board of Directors | 2002 – 2007 | |
| Board of Directors | 2015 – 2018 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2009 – 2013 | |
| Board of Directors | 2002 – 2013 | |
| Board of Directors | 2003 – 2007 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2025 | |
| Company | 100% | 100% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Eurofins Genomics Denmark A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Brian Sørensen | Chief Executive Officer | 0 companies |
| Torben Falck Ørntoft | Founder | 0 companies |
| Jacob Sickmann Ransborg | Chief Executive Officer | 0 companies |
| Morten Melbye | Chief Executive Officer | 0 companies |
| Thomas Thykjær Andersen | Founder | 0 companies |
| Daniel Schougaard Langhoff | Chief Executive Officer | 0 companies |
| Mogens Kruhøffer | Founder | 0 companies |
| Jørn Renz Enggaard | Board of Directors | 0 companies |
| Sonja Maria Wiedemann | Board of Directors | 0 companies |
| Kurt Hedegaard Carstensen | Board of Directors | 0 companies |
| Carsten Kultoft Lorentsen | Board of Directors | 0 companies |
| Svend Aage Linde | Chairman | 0 companies |
| Lars Christian Caspersen | Board of Directors | 0 companies |
| Jørgen Winther Pedersen | Board of Directors | 0 companies |
| Michael Hadem | Board of Directors | 0 companies |
| Bruno Francis Claude Poddevin | Board of Directors | 0 companies |
| Claus Thorsen | Board of Directors | 0 companies |
| Thomas Gjelsnes | Board of Directors | 0 companies |
| Stefánia Pcolová | Board of Directors | 0 companies |
| Niels Stampe Rüdiger | Board of Directors | 0 companies |
| Villy Helleskov | Board of Directors | 0 companies |
| Ulrich August Werner Kühle | Board of Directors | 0 companies |
| Arne Josefsen Rolighed | Board of Directors | 0 companies |